

# David R Jayne

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3215078/david-r-jayne-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52  
papers

2,847  
citations

24  
h-index

53  
g-index

65  
ext. papers

4,209  
ext. citations

5.8  
avg, IF

5.17  
L-index

#	Paper	IF	Citations
52	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1400-1412	9.5	488
51	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159	2.4	344
50	Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1036-43	2.4	253
49	Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 542-8		223
48	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. <i>Rheumatology</i> , <b>2014</b> , 53, 2306-9	3.9	186
47	Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 177-84	2.4	143
46	ANCA-associated vasculitis. <i>Nature Reviews Disease Primers</i> , <b>2020</b> , 6, 71	51.1	117
45	Avacopan for the Treatment of ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 599-609	59.2	109
44	Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 526-31	2.4	104
43	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , <b>2015</b> , 54, 471-81	3.9	73
42	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 904-13	13.3	71
41	Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1064-1069	2.4	61
40	Mortality in Wegener's granulomatosis: a bimodal pattern. <i>Rheumatology</i> , <b>2011</b> , 50, 697-702	3.9	58
39	Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. <i>Autoimmunity</i> , <b>1991</b> , 11, 1-6	3	56
38	The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , <b>2012</b> , 12, 204-9	13.6	49
37	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 2170-2177	11.5	41
36	Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>RMD Open</i> , <b>2019</b> , 5, e000905	5.9	37

35	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 634-640	2.4	35
34	Relapsing polychondritis: a clinical review for rheumatologists. <i>Rheumatology</i> , <b>2018</b> , 57, 1525-1532	3.9	34
33	Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. <i>JMIR Research Protocols</i> , <b>2020</b> , 9, e16664	2	34
32	Assessment of damage in vasculitis: expert ratings of damage. <i>Rheumatology</i> , <b>2009</b> , 48, 823-7	3.9	29
31	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 721-726	4.1	29
30	Current and emerging treatment options in the management of lupus. <i>ImmunoTargets and Therapy</i> , <b>2016</b> , 5, 9-20	9	28
29	Comparison of the Phenotype and Outcome of Granulomatosis with Polyangiitis Between UK and Japanese Cohorts. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 216-222	4.1	24
28	[F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. <i>European Urology</i> , <b>2017</b> , 71, 926-933	10.2	22
27	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , <b>2017</b> , 3, e000449	5.9	16
26	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1333-1339	2.4	16
25	Rheumatological complications of Covid 19. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102883	13.6	16
24	Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. <i>Journal of Clinical Rheumatology</i> , <b>2019</b> , 25, 217-223	1.1	15
23	Renal manifestations of the antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , <b>2009</b> , 11, 52-60	4.9	13
22	Genetic Variants in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Bayesian Approach and Systematic Review. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	12
21	Testing for autoimmunity in humans. <i>Toxicology Letters</i> , <b>2002</b> , 127, 93-100	4.4	12
20	Con: The use of calcineurin inhibitors in the treatment of lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 1567-71	4.3	12
19	Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. <i>Rheumatology</i> , <b>2019</b> , 58, 889-896	3.9	12
18	Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa006	1.1	11

17	Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,	9.5	10
16	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	10
15	Anabolic steroid-induced rhabdomyolysis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , <b>2005</b> , 66, 362	0.8	7
14	A historical essay on detection of anti-neutrophil cytoplasmic antibodies. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30 Suppl 1, i8-13	4.3	6
13	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1314-1325	5.3	6
12	Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes. <i>Patient Related Outcome Measures</i> , <b>2019</b> , 10, 37-42	2.9	4
11	Antiphospholipid syndrome. <i>BMJ, The</i> , <b>2015</b> , 350, h1426	5.9	4
10	Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2015</b> , 7, 234-46	3.8	4
9	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , <b>2019</b> , 86, 363-368	2.9	4
8	Respiratory subtype of relapsing polychondritis frequently presents as difficult asthma: a descriptive study of respiratory involvement in relapsing polychondritis with 13 patients from a single UK centre. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	4
7	Why do we need a new journal in autoimmunity?. <i>Journal of Autoimmune Diseases</i> , <b>2004</b> , 1, 1		1
6	Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	1
5	Pericoronary and periaortic adipose tissue density are associated with inflammatory disease activity in Takayasu arteritis and atherosclerosis. <i>European Heart Journal Open</i> , <b>2021</b> , 1, oeab019		1
4	Use of Glomerular CD68+ Cells as a Surrogate Marker for Endocapillary Hypercellularity in Lupus Nephritis.. <i>Kidney International Reports</i> , <b>2022</b> , 7, 841-847	4.1	0
3	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 1566-7	4.3	0
2	Raised Intracranial Pressure Due to Compression of the Jugular Vein in Wegener's Granulomatosis. <i>Neuro-Ophthalmology</i> , <b>2008</b> , 32, 309-311	0.9	
1	Idiopathic aortitis presenting as pyrexia of unknown origin and delirium. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , <b>2018</b> , 79, 586-587	0.8	